Industry Overview

Biopsy devices market was valued at $2.8 billion in 2025 and is projected to reach $4.9 billion by 2035, growing at a CAGR of 5.9% during the forecast period (2026-2035). The market is growing due to the rising incidence of cancer, increased demand for minimally invasive procedures, and technological advancements like robotic and image-guided biopsies. Key growth factors also include improved healthcare infrastructure, greater public awareness of cancer screening, and more favorable reimbursement policies. Conversely, market growth is hampered by the high cost of some procedures, risks of infection, and complex regulatory environments.

Market Dynamics

Rising Prevalence of Cancer and Chronic Diseases

One of the most significant drivers propelling the global biopsy devices market is the increasing prevalence of cancer and other chronic diseases worldwide. According to the WHO, cancer remains one of the leading causes of death globally, with breast, lung, prostate, and colorectal cancers being the most common. The growing incidence of these diseases has created a higher demand for early and accurate diagnostic techniques, where biopsy plays a critical role in confirming malignancies. Furthermore, the rising awareness of early detection and screening programs, especially in developed nations like the U.S., Germany, and Japan, has led to an upsurge in biopsy procedures, fueling the demand for advanced and minimally invasive biopsy devices.

Technological Advancements in Biopsy Procedures

Continuous technological innovation is another major driver supporting market expansion. The shift toward minimally invasive biopsy techniques such as vacuum-assisted, image-guided, and robotic-assisted biopsy systems is revolutionizing diagnostic accuracy while reducing patient discomfort and recovery time. The integration of ultrasound, CT, and MRI imaging technologies in biopsy procedures has improved precision, enabling real-time tissue sampling and higher diagnostic yield. Additionally, manufacturers are developing disposable and automated biopsy devices to ensure sterility, consistency, and reduced cross-contamination risks. These advancements are attracting significant investments from hospitals and diagnostic centers globally, creating long-term growth opportunities in the biopsy devices market.

Growing Healthcare Expenditure and Emerging Market Penetration

Increasing healthcare investments, improved reimbursement policies, and expanding diagnostic infrastructure, particularly in emerging economies across Asia-Pacific and Latin America, are accelerating market growth. Countries such as China, India, and Brazil are witnessing a surge in cancer screening initiatives supported by government and private healthcare organizations. Additionally, the growing establishment of diagnostic imaging centers and ambulatory surgical centers in these regions is driving demand for cost-effective and advanced biopsy instruments. With global healthcare systems emphasizing early diagnosis and outpatient procedures, the demand for biopsy devices is expected to rise significantly, contributing to the overall expansion of the global biopsy devices market over the forecast period.

Market Segmentation

• Based on the type, the market is segmented into needle-based biopsy instruments, procedure trays, localization wires, and other products.
• Based on the application, the market is segmented into breast biopsy, lung biopsy, colorectal biopsy, prostate biopsy, and others.
• Based on the end user, the market is segmented into hospitals, diagnostic & imaging centers, ambulatory surgical centers, and others.

Needle-Based Biopsy Instruments Segment to Grow at a Considerable Market Share

Needle-based biopsy instruments are the single largest segment poised to lead the global biopsy devices market. They dominate because needle biopsies are minimally invasive, cost-effective, widely applicable across tissue types (breast, lung, prostate, colorectal), and compatible with image-guided techniques that improve diagnostic accuracy. Continuous product innovation (vacuum-assisted and core-needle designs), growing cancer screening programs, rising incidence of cancer globally, and strong adoption by hospitals and diagnostic centers for outpatient and inpatient procedures further boost demand. Additionally, needle systems require lower capital investment than large imaging platforms, offer quicker patient recovery and shorter procedure times, and fit into expanding point-of-care and ambulatory settings, making them the go-to device category for clinicians and healthcare systems globally.

Breast Biopsy: A Key Segment in Market Growth

The breast biopsy segment is emerging as the key growth driver among applications. This can be attributed to the increasing prevalence of breast cancer worldwide, combined with growing awareness about early diagnosis and minimally invasive procedures. Technological advancements in biopsy devices, such as vacuum-assisted and core needle biopsy systems, have significantly improved the accuracy, safety, and patient comfort during breast tissue sampling, further driving adoption. Additionally, government initiatives and campaigns promoting breast cancer screening programs in both developed and developing regions are accelerating the demand for efficient biopsy solutions.

Hospitals and specialized diagnostic centers are increasingly adopting advanced breast biopsy technologies to facilitate early detection, reduce surgical interventions, and enhance patient outcomes. As a result, breast biopsy procedures are expected to register robust growth during the forecast period, outpacing other biopsy applications like lung, colorectal, and prostate biopsies. The combination of rising disease incidence, technological innovation, and supportive healthcare policies positions the breast biopsy segment as the leading contributor to market expansion in the coming years.

Regional Outlook

The global biopsy devices market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global biopsy devices market, holding the largest share due to its advanced healthcare infrastructure, high cancer prevalence, and early adoption of innovative diagnostic technologies. The country’s leadership is supported by major players such as Becton Dickinson, Hologic, Boston Scientific, Cook Medical, and Cardinal Health, which drive continuous product development and availability. High incidences of breast, lung, and prostate cancers generate strong clinical demand for needle-based, vacuum-assisted, and image-guided biopsy procedures, while favorable reimbursement policies encourage the adoption of minimally invasive techniques.

Additionally, the presence of leading research institutions and cancer centers, along with widespread patient awareness programs, enhances the integration of advanced biopsy systems into routine diagnostics. The combination of robust regulatory frameworks, high healthcare spending, and a focus on outpatient and precision medicine ensures that the U.S. maintains its dominant position in the global biopsy devices market.

Market Players Outlook

The major companies operating in the global biopsy devices market include Lonza Group, Merck KGaA, Sartorius AG, STEMCELL Technologies, and Thermo Fisher Scientific, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In October 2025, CND Life Sciences received FDA Breakthrough Device Designation for its Syn-One Test, which assists in diagnosing synucleinopathies in patients aged 40 and older with relevant neurological conditions. This designation helps expedite development and review processes for medical devices, provided they show potential for significant improvements in the treatment or diagnosis of serious conditions. The program offers access to FDA resources and priority review for premarket submissions.
• In July 2025, Single Pass Inc. launched the B-S.A.F.E. global post-market evaluation for its SinglePass electrocautery biopsy closure device. This evaluation aims to generate real-world evidence of its effectiveness in preventing unintended bleeding after biopsies, a common post-procedure risk that can lead to additional interventions and increased healthcare costs. The SinglePass device cauterizes the biopsy tract immediately after tissue extraction, potentially reducing bleeding complications and improving procedural efficiency.
• In November 2024, Mammotome introduced the Mammotome AutoCoreTM Single Insertion Core Biopsy System, the first automated spring-loaded core needle device available. This innovative system enhances breast biopsy technology by offering significant advantages over traditional devices, such as time-saving for physicians and improved patient experience. The system's single insertion design simplifies ultrasound-guided biopsies, allowing for efficient, one-button automation of sampling steps and touchless tissue transfer. Additionally, it streamlines the process by eliminating the need for manual arming and allowing for direct placement of tissue samples into formalin, all while helping physicians maintain focus on the lesion for precise sampling.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global biopsy devices market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.